Eisai presents new Leqembi analyses

Japanese drugmaker Eisai (TYO: 4523) and its partner Biogen (Nasdaq: BIIB) have presented new analyses on Leqembi (lecanemab), the Alzheimer’s drug that gained US approval in January.

The analyses are from the Clarity AD Phase III trial, which met its primary endpoint of slowing cognitive decline, along with all key secondary endpoints, with highly statistically significant results.

These new analyses are on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H (combined cerebral microhemorrhages, superficial siderosis, and intracerebral hemorrhages of more than 1cm in diameter), and caregiver burden and health-related quality of life.